{
    "clinical_study": {
        "@rank": "85828", 
        "arm_group": [
            {
                "arm_group_label": "DCVAC/OvCa in parallel with chemotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Combination therapy with DCVAC/OvCa and Standard of Care"
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard of Care carboplatin and gemcitabine"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether DCVAC/OvCa added to Standard of Care\n      chemotherapy (carboplatin and gemcitabine as second line chemotherapy) may result in\n      prolongation of progression free survival (PFS)."
        }, 
        "brief_title": "Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ovarian Neoplasms", 
            "Ovarian Cancer (OvCa)", 
            "Ovarian Epithelial Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Carcinoma", 
                "Ovarian Neoplasms", 
                "Neoplasms, Glandular and Epithelial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Females 18 years old and older\n\n          -  Patients with histologically confirmed,  International Federation of Gynecology and\n             Obstetrics (FIGO) stage III epithelial ovarian, primary peritoneal or fallopian tube\n             carcinoma (serous, endometrioid or mucinous), who had complete remission after first\n             line platinum (Pt)-based chemotherapy and are selected to receive second line\n             Standard of Care chemotherapy\n\n          -  Radiologically confirmed relapse after >6 months of remission (Platinum-sensitive\n             patients), found up to 4 weeks prior study entry.\n\n          -  The patient must have at least one measureable target lesion as defined by the\n             Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria to be eligible for\n             enrolment in the study\n\n        Exclusion Criteria:\n\n          -  FIGO I,II,IV epithelial ovarian cancer\n\n          -  FIGO III clear cells epithelial ovarian cancer\n\n          -  Non-epithelial ovarian cancer\n\n          -  Borderline tumors (tumors of low malignant potential)\n\n          -  Prior or current systemic anti-cancer therapy for ovarian cancer [for example\n             chemotherapy, monoclonal antibody therapy , tyrosine kinase inhibitor therapy,\n             vascular endothelial growth factor (VEGF) therapy or hormonal therapy] except first\n             line Platinum-based chemotherapy (with or without bevacizumab)\n\n          -  Previous radiotherapy to the abdomen and pelvis\n\n          -  Malignancy other than epithelial ovarian cancer, except those that have been in\n             clinical remission (CR) for a minimum of 3 years, and except carcinoma in-situ of the\n             cervix or non-melanoma skin carcinomas"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02107950", 
            "org_study_id": "SOV02", 
            "secondary_id": "2013-001323-38"
        }, 
        "intervention": [
            {
                "arm_group_label": "DCVAC/OvCa in parallel with chemotherapy", 
                "description": "DCVAC/OvCa is the experimental therapy added on to Carboplatin and Gemcitabine", 
                "intervention_name": "DCVAC/OvCa in parallel with chemotherapy", 
                "intervention_type": "Biological", 
                "other_name": [
                    "DCVAC/OvCa", 
                    "carboplatin and gemcitabine"
                ]
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "description": "Carboplatin and Gemcitabine is Standard of Care First Line Chemotherapy", 
                "intervention_name": "Standard of Care", 
                "intervention_type": "Drug", 
                "other_name": "Carboplatin and Gemcitabine"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ovarian", 
            "Platinum Sensitive", 
            "Epithelial"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brno", 
                        "country": "Czech Republic", 
                        "zip": "625 00"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brno", 
                        "country": "Czech Republic", 
                        "zip": "656 53"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ceske Budejovice", 
                        "country": "Czech Republic", 
                        "zip": "370 01"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hradec Kr\u00e1lov\u00e9", 
                        "country": "Czech Republic", 
                        "zip": "500 05"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Olomouc", 
                        "country": "Czech Republic", 
                        "zip": "755 20"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ostrava", 
                        "country": "Czech Republic", 
                        "zip": "708 52"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic", 
                        "zip": "128 08"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 5", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cologne", 
                        "country": "Germany", 
                        "zip": "50931"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "zip": "01307"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Erlangen", 
                        "country": "Germany", 
                        "zip": "91 054"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "041 03"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bialystok", 
                        "country": "Poland", 
                        "zip": "15-276"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gliwice", 
                        "country": "Poland", 
                        "zip": "45-101"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krakow", 
                        "country": "Poland", 
                        "zip": "31-501"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lublin", 
                        "country": "Poland", 
                        "zip": "20-081"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Poznan", 
                        "country": "Poland", 
                        "zip": "60-569"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Czech Republic", 
                "Germany", 
                "Poland"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial DCVAC/OvCa Added to Standard Chemotherapy in Women With Relapsed Platinum Sensitive Epithelial Ovarian Carcinoma", 
        "overall_contact": {
            "email": "kapsa.@sotio.com", 
            "last_name": "Richard Kapsa", 
            "phone": ": (+420) 2241 74448"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Czech Republic: State Institute for Drug Control", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Germany: Paul-Ehrlich-Institut"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Determine median progression free survival", 
            "safety_issue": "No", 
            "time_frame": "72 Week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02107950"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival (all causes)", 
                "safety_issue": "Yes", 
                "time_frame": "56, 64, 72 weeks"
            }, 
            {
                "measure": "Objective Response Rate", 
                "safety_issue": "No", 
                "time_frame": "8, 16, 24, 32, 40, 48, 56. 64. 72 weeks"
            }, 
            {
                "measure": "Biological Progression Free Interval", 
                "safety_issue": "No", 
                "time_frame": "6, 12, 18, 24, 36, 42, 48, 56, 64, 72 weeks"
            }, 
            {
                "measure": "Immunological Response", 
                "safety_issue": "No", 
                "time_frame": "24, 48, 72 weeks"
            }, 
            {
                "measure": "Frequency of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "8, 16, 24, 32, 40, 48, 56. 64. 72 weeks"
            }
        ], 
        "source": "Sotio a.s.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sotio a.s.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}